Journal
VACCINE
Volume 24, Issue 44-46, Pages 6629-6631Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2006.05.035
Keywords
influenza; influenza vaccine; elderly; improved immunogenicity; tolerability; virosomal; adjuvant
Categories
Ask authors/readers for more resources
Several approaches are currently being pursued in order to improve the efficacy of influenza vaccines in elderly individuals and others who have impaired immune responses to conventional influenza vaccines. There are two influenza vaccines available for elderly subjects: Fluad (R) (Chiron) and Invivac (R) (Solvay Pharmaceuticals). The present clinical study was a randomized, endpoint-blind, parallel group study in elderly subjects aged 61 years and older to investigate the safety and immunogenicity of these vaccines as compared to a standard influenza vaccine Invivac (R) (Solvay Pharmaceuticals). The three vaccines had similar immunogenicity results, whereas the tolerability profile of Invivac was better as compared to Fluad. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available